kabutan

Cyfuse Biomedical shares surge on report of world-first knee joint regenerative medicine trial in July

Mon Apr 20, 2026 10:14 am JST Catalyst

Cyfuse Biomedical K.K. <4892> surged at the open. The Nikkei reported on April 19 that Keio University and Fujita Health University will launch a physician-led clinical trial in July to simultaneously repair bone and cartilage in knee joints. Cyfuse, which provides the bio-3D printing technology for the trial, saw its shares buoyed by the report. The project marks the world-first implementation of regenerative medicine using 3D-printed structures created from donor-derived adipose tissue cells for transplantation into affected areas.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles